The DOI matches its Crossref record.
Growth Hormone Treatment and Risk of Second Neoplasms in the Childhood Cancer Survivor
Abstract
Context: GH deficiency is common in childhood cancer survivors. In a previous report, although we did not find an increase in the risk of disease recurrence in survivors treated with GH, GH-treated survivors did have an increased risk of developing a second neoplasm (SN) (rate ratio, 3.21). Objective: In this analysis, we have reassessed the risk of GH-treated survivors developing an SN after an additional 32 months of follow-up. Design and Setting: We conducted a retrospective cohort multicenter study. Patients: Among a total of 14,108 survivors who were enrolled in the Childhood Cancer Survivor Study, a retrospective cohort of 5-yr survivors of childhood cancer, we identified 361 who were treated with GH. Main Outcome: We assessed the risk of developing an SN. Results: During the extended follow-up, five new SN developed in survivors treated with GH, for a total of 20 SN, all solid tumors. Using a time-dependent Cox model, the rate ratio of GH-treated survivors developing an SN, compared with non-GH-treated survivors, was 2.15 (95% confidence interval, 1.3–3.5; P < 0.002). Meningiomas were the most common SN (n = 9) among the GH-treated group. Conclusion: Although cancer survivors treated with GH appear to have an increased risk of developing SN compared with survivors not so treated, the elevation of risk due to GH use appears to diminish with increasing length of follow-up. Continued surveillance is essential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Molitch, M. E., Clemmons, D. R., Malozowski, S., Merriam, G. R., & Vance, M. L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0179 · Cited by 1,047
Long-term safety of recombinant human growth hormone in children
Bell, J., Parker, K. L., Swinford, R. D., Hoffman, A. R., Maneatis, T., & Lippe, B. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0178 · Cited by 301
Sklar, C. A., Antal, Z., Chemaitilly, W., Cohen, L. E., Follin, C., Meacham, L. R., & Murad, M. H. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01175 · Cited by 224
Self-citationWong, S. C., Dobie, R., Altowati, M. A., Werther, G. A., Farquharson, C., & Ahmed, S. F. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1026 · Cited by 163
Cancer risks in patients treated with growth hormone in childhood: the SAGhE European cohort study
Swerdlow, A. J., Cooke, R., Beckers, D., Borgström, B., Butler, G., Carel, J.-C., Cianfarani, S., Clayton, P., Coste, J., Deodati, A., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2046 · Cited by 153
“Potential effects on leukemia (5, 6) and other malignancy (1) risks have been suggested, and second primary malignancy risk has been shown raised in patients receiving GH after childhood cancer (7, 8).”
BackgroundInfluentialLong-term safety of recombinant human growth hormone in Turner syndrome
Bolar, K., Hoffman, A. R., Maneatis, T., & Lippe, B. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1723 · Cited by 116
Boguszewski, M. C. S., Boguszewski, C. L., Chemaitilly, W., Cohen, L. E., Gebauer, J., Higham, C., Hoffman, A. R., Polak, M., Yuen, K. C. J., Alos, N., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-21-1186 · Cited by 117
Child, C. J., Zimmermann, A. G., Chrousos, G. P., Cummings, E., Deal, C. L., Hasegawa, T., Jia, N., Lawrence, S., Linglart, A., Loche, S., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01189 · Cited by 80
Child, C. J., Conroy, D., Zimmermann, A. G., Woodmansee, W. W., Erfurth, E. M., & Robison, L. L. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-1123 · Cited by 58
Self-citationQuigley, C. A., Child, C. J., Zimmermann, A. G., Rosenfeld, R. G., Robison, L. L., & Blum, W. F. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00214 · Cited by 33
Self-citationvan Varsseveld, N. C., van Bunderen, C. C., Franken, A. A. M., Koppeschaar, H. P. F., van der Lely, A. J., & Drent, M. L. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1764 · Cited by 26
Metadata
- Authors
- Ergun-Longmire, B., Mertens, A. C., Mitby, P., Qin, J., Heller, G., Shi, W., Yasui, Y., Robison, L. L., & Sklar, C. A.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2006-09-01
- Volume
- 91
- Issue
- 9
- Pages
- 3494-3498
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2086789132
- Cited by
- 274
- References
- 0
- FWCI
- 8.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
